MESOBLAST RAISES NEW CAPITAL FOR COMMERCIAL …

2 days ago · Melbourne, Australia; January 14 and New York, USA; January 13, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for …

$260
OFF

Mesoblast Shares Dive On Discounted Placement — Capital Brief

2 weeks from now

2 days ago · The news: Dual-listed biotech Mesoblast has raised $260 million through a private placement to fund the commercial launch of its Ryoncil therapy in the US. The numbers: The …

capitalbrief.com

$260
OFF

Mesoblast Raises $260M In Global Private Placement To Accelerate ...

2 weeks from now

2 days ago · Mesoblast (ASX:MSB) announced a global private placement, raising $260 million at $2.50 per share. The round was primarily supported by the company's major shareholders in …

grafa.com

$50
OFF

Mesoblast Option To Issue Up To US$50 Million Convertible

2 weeks from now

Sep 30, 2024 · Mesoblast at its sole discretion, to issue up to US$50 million of convertible notes in tranches of US$10 million at any time following an FDA approval of RYONCIL for a 90-day …

globenewswire.com

$260
OFF

Mesoblast Secures $260 Million In Capital Raising To Drive Growth

2 weeks from now

2 days ago · Mesoblast Limited (ASX: MSB) has successfully completed a $260 million capital raise, supported by its existing shareholders. The funds are earmarked to bolster key …

kapitales.com.au

$50
OFF

#Mesoblast Secures $50 Million Funding With FDA Nod For Ryoncil ...

2 weeks from now

New York, Sept. 29, 2024 ?? Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines aimed at treating inflammatory diseases, has announced a …

csimarket.com

$97
OFF

PLACEMENT AND ACCELERATED NON-RENOUNCEABLE …

2 weeks from now

PLACEMENT AND ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFER TO RAISE UP TO A$97.0M Melbourne, Australia; December 4, 2023: Mesoblast Limited (ASX:MSB; …

afr.com

FAQs about MESOBLAST RAISES NEW CAPITAL FOR COMMERCIAL … Coupon?

Will Mesoblast join the NASDAQ Biotechnology Index in 2024?

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. ...

Will Mesoblast complete its accelerated non-renounceable entitlement offer?

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launched on 4 December, 2023 (Entitlement Offer). ...

What happened to Mesoblast limited?

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. On 30 June 2024, the AU$1.5b market-cap company posted a loss of US$88m for its most recent financial year. ...

How did ASX-listed shares of Mesoblast perform in early trading?

ASX-listed shares of Mesoblast were up 2.2% at $1.15 in early trading. The context: Mesoblast CEO Silviu Itescu thanked George for ensuring the company is well-capitalised for commercial product launch if it gets the regulatory nod. ...

Why are Mesoblast shares down 85 percent since August 2020?

Mesoblast shares are down 85 per cent since August 2020, and its last reported net debt position of $US32.9 million means it needs to find funding sources. The disastrous pandemic-era floats of Cleanspace and Laybuy have put pressure on the small-cap stock promotion industry. ...

Where is Mesoblast based?

Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). ...